{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T17:47:27Z","timestamp":1767116847450,"version":"3.45.0"},"reference-count":67,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,7,7]],"date-time":"2023-07-07T00:00:00Z","timestamp":1688688000000},"content-version":"vor","delay-in-days":187,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003769","name":"Eisai","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003769","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000871","name":"Mayo Clinic","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020123","name":"Martin Family Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020123","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Epilepsy & Behavior Reports"],"published-print":{"date-parts":[[2023]]},"DOI":"10.1016\/j.ebr.2023.100612","type":"journal-article","created":{"date-parts":[[2023,7,7]],"date-time":"2023-07-07T21:36:52Z","timestamp":1688765812000},"page":"100612","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Acute seizure therapies in people with epilepsy: Fact or fiction? A U.S. Perspective"],"prefix":"10.1016","volume":"23","author":[{"given":"William O.","family":"Tatum","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tracy","family":"Glauser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jurriaan M.","family":"Peters","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amit","family":"Verma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah","family":"Weatherspoon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Selim","family":"Benbadis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Danielle A.","family":"Becker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vinay","family":"Puri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Smith","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sunita N.","family":"Misra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adrian L.","family":"Rabinowicz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Enrique","family":"Carrazana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.ebr.2023.100612_b0005","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1097\/NRL.0000000000000140","article-title":"Burden of seizure clusters on patients with epilepsy and caregivers: survey of patient, caregiver, and clinician perspectives","volume":"22","author":"Penovich","year":"2017","journal-title":"Neurologist"},{"key":"10.1016\/j.ebr.2023.100612_b0010","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.seizure.2018.05.013","article-title":"Seizure cluster: definition, prevalence, consequences, and management","volume":"68","author":"Jafarpour","year":"2019","journal-title":"Seizure"},{"issue":"2","key":"10.1016\/j.ebr.2023.100612_b0015","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1097\/WCO.0000000000000177","article-title":"Seizure clusters: characteristics and treatment","volume":"28","author":"Haut","year":"2015","journal-title":"Curr Opin Neurol"},{"issue":"9","key":"10.1016\/j.ebr.2023.100612_b0020","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1007\/s40263-022-00940-2","article-title":"Benzodiazepines in the management of seizures and status epilepticus: a review of routes of delivery, pharmacokinetics, efficacy, and tolerability","volume":"36","author":"Kienitz","year":"2022","journal-title":"CNS Drugs"},{"issue":"4","key":"10.1016\/j.ebr.2023.100612_b0025","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1111\/epi.16847","article-title":"Overcoming the challenges of developing an intranasal diazepam rescue therapy for the treatment of seizure clusters","volume":"62","author":"Cloyd","year":"2021","journal-title":"Epilepsia"},{"issue":"8","key":"10.1016\/j.ebr.2023.100612_b0030","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.3390\/jcm10081754","article-title":"Time is brain: acute control of repetitive seizures and status epilepticus using alternative routes of administration of benzodiazepines","volume":"10","author":"Almohaish","year":"2021","journal-title":"J Clin Med"},{"key":"10.1016\/j.ebr.2023.100612_b0035","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.jconrel.2016.07.001","article-title":"A review of intranasal formulations for the treatment of seizure emergencies","volume":"237","author":"Kapoor","year":"2016","journal-title":"J Control Release"},{"key":"10.1016\/j.ebr.2023.100612_b0040","doi-asserted-by":"crossref","DOI":"10.1016\/j.yebeh.2020.107391","article-title":"Seizure clusters, rescue treatments, seizure action plans: unmet needs and emerging formulations","volume":"112","author":"Gidal","year":"2020","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.ebr.2023.100612_b0045","unstructured":"European Medicines Agency. Nasolam and associated names, https:\/\/www.ema.europa.eu\/en\/medicines\/human\/referrals\/nasolam-associated-names; 2022 [accessed May 25, 2023]."},{"key":"10.1016\/j.ebr.2023.100612_b0050","unstructured":"Laboratorios Lesvi SL. Buccolam summary of product characteristics (midazolam hydrochloride oromucosal solution). Summary of Product Characteristics. Barcelona, Spain: Laboratorios Lesvi, S.L.; 2023."},{"issue":"10","key":"10.1016\/j.ebr.2023.100612_b0055","doi-asserted-by":"crossref","first-page":"e156","DOI":"10.1111\/j.1528-1167.2011.03201.x","article-title":"Benzodiazepines in the acute management of seizures with autonomic manifestations: anticipate complications!","volume":"52","author":"Lacroix","year":"2011","journal-title":"Epilepsia"},{"issue":"6","key":"10.1016\/j.ebr.2023.100612_b0060","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1111\/j.1528-1167.2007.01087.x","article-title":"Autonomic status epilepticus in Panayiotopoulos syndrome and other childhood and adult epilepsies: a consensus view","volume":"48","author":"Ferrie","year":"2007","journal-title":"Epilepsia"},{"issue":"8","key":"10.1016\/j.ebr.2023.100612_b0065","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1111\/j.1528-1167.2006.00607.x","article-title":"Experimental and clinical evidence for loss of effect (tolerance) during prolonged treatment with antiepileptic drugs","volume":"47","author":"Loscher","year":"2006","journal-title":"Epilepsia"},{"key":"10.1016\/j.ebr.2023.100612_b0070","unstructured":"Bausch Health US, LLC. Diastat\u00ae C-IV (diazepam rectal gel). Full Prescribing Information. Bridgewater, NJ: Bausch Health US, LLC; 2023."},{"key":"10.1016\/j.ebr.2023.100612_b0075","unstructured":"Neurelis, Inc. VALTOCO\u00ae (diazepam nasal spray). Full Prescribing Information. San Diego, CA: Neurelis, Inc.; 2023."},{"key":"10.1016\/j.ebr.2023.100612_b0080","unstructured":"UCB, Inc. Nayzilam\u00ae (midazolam nasal spray). Full Prescribing Information. Smyrna, GA: UCB, Inc.; 2023."},{"issue":"7","key":"10.1016\/j.ebr.2023.100612_b0085","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1111\/epi.17249","article-title":"Lack of clinically relevant differences in safety and pharmacokinetics after second-dose administration of intranasal diazepam within 4 h for acute treatment of seizure clusters: A population analysis","volume":"63","author":"Cascino","year":"2022","journal-title":"Epilepsia"},{"issue":"10","key":"10.1016\/j.ebr.2023.100612_b0090","doi-asserted-by":"crossref","first-page":"2485","DOI":"10.1111\/epi.17041","article-title":"Final results from a phase 3, long-term, open-label, repeat-dose safety study of diazepam nasal spray for seizure clusters in patients with epilepsy","volume":"62","author":"Wheless","year":"2021","journal-title":"Epilepsia"},{"issue":"11","key":"10.1016\/j.ebr.2023.100612_b0095","first-page":"1610","article-title":"An open-label study of repeated use of diazepam rectal gel (Diastat) for episodes of acute breakthrough seizures and clusters: safety, efficacy, and tolerance","volume":"40","author":"Mitchell","year":"1999","journal-title":"North American Diastat Group Epilepsia"},{"issue":"9","key":"10.1016\/j.ebr.2023.100612_b0100","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1111\/epi.16300","article-title":"Safety and efficacy of midazolam nasal spray in the outpatient treatment of patients with seizure clusters: an open-label extension trial","volume":"60","author":"Wheless","year":"2019","journal-title":"Epilepsia"},{"issue":"9","key":"10.1016\/j.ebr.2023.100612_b0105","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1111\/epi.15159","article-title":"Safety and efficacy of midazolam nasal spray in the outpatient treatment of patients with seizure clusters\u2014a randomized, double-blind, placebo-controlled trial","volume":"60","author":"Detyniecki","year":"2019","journal-title":"Epilepsia"},{"issue":"1","key":"10.1016\/j.ebr.2023.100612_b0110","doi-asserted-by":"crossref","first-page":"48","DOI":"10.5698\/1535-7597-16.1.48","article-title":"Evidence-based guideline: treatment of convulsive status epilepticus in children and adults: report of the guideline committee of the American Epilepsy Society","volume":"16","author":"Glauser","year":"2016","journal-title":"Epilepsy Curr"},{"issue":"5","key":"10.1016\/j.ebr.2023.100612_b0115","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1111\/j.1600-0404.2009.01170.x","article-title":"Pharmacokinetics and tolerability of intranasal diazepam and midazolam in healthy adult volunteers","volume":"120","author":"Ivaturi","year":"2009","journal-title":"Acta Neurol Scand"},{"year":"2019","series-title":"Interactions of B-lactoglobulin with small molecules","author":"Xiang","key":"10.1016\/j.ebr.2023.100612_b0120"},{"issue":"3","key":"10.1016\/j.ebr.2023.100612_b0125","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1111\/epi.16449","article-title":"Bioavailability and safety of diazepam intranasal solution compared to oral and rectal diazepam in healthy volunteers","volume":"61","author":"Hogan","year":"2020","journal-title":"Epilepsia"},{"key":"10.1016\/j.ebr.2023.100612_b0130","unstructured":"Neurelis I. Neurelis Files New Drug Application With the FDA for Valtoco (Diazepam Nasal Spray), an Investigational Treatment for Pediatric, Adolescent and Adult Epilepsy Patients, https:\/\/neurelis.com\/neurelis-news\/neurelis-files-new-drug-application-fda-valtocotm-nasal-spray-investigational-treatment-pediatric; 2018 [accessed January 4, 2023]."},{"key":"10.1016\/j.ebr.2023.100612_b0135","unstructured":"Lundbeck. Onfi\u00ae (clobazam). Full Prescribing Information. Deerfield, IL: Lundbeck; 2021."},{"key":"10.1016\/j.ebr.2023.100612_b0140","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.seizure.2017.10.007","article-title":"Rescue medications in epilepsy patients: a family perspective","volume":"52","author":"Gainza-Lein","year":"2017","journal-title":"Seizure"},{"key":"10.1016\/j.ebr.2023.100612_b0145","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.eplepsyres.2017.04.016","article-title":"Prevalence and risk factors of seizure clusters in adult patients with epilepsy","volume":"133","author":"Chen","year":"2017","journal-title":"Epilepsy Res"},{"issue":"1","key":"10.1016\/j.ebr.2023.100612_b0150","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.neurol.2015.11.003","article-title":"Epidemiology of epilepsy","volume":"172","author":"Behr","year":"2016","journal-title":"Rev Neurol (Paris)"},{"key":"10.1016\/j.ebr.2023.100612_b0155","unstructured":"Centers for Disease Control and Prevention. Epilepsy Data and Statistics, https:\/\/www.cdc.gov\/epilepsy\/data\/index.html; [accessed April 22, 2019]."},{"issue":"12","key":"10.1016\/j.ebr.2023.100612_b0160","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.1111\/epi.14596","article-title":"The epidemiology of drug-resistant epilepsy: a systematic review and meta-analysis","volume":"59","author":"Kalilani","year":"2018","journal-title":"Epilepsia"},{"issue":"1","key":"10.1016\/j.ebr.2023.100612_b0165","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.yebeh.2005.08.018","article-title":"Seizure clustering","volume":"8","author":"Haut","year":"2006","journal-title":"Epilepsy Behav"},{"issue":"6","key":"10.1016\/j.ebr.2023.100612_b0170","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1177\/1942602X18806824","article-title":"Introducing NASN's new evidence-based clinical guideline: students with seizures and epilepsy","volume":"33","author":"Lepkowski","year":"2018","journal-title":"NASN Sch Nurse"},{"key":"10.1016\/j.ebr.2023.100612_b0175","unstructured":"Epilepsy Foundation. Seizure Safe Schools, https:\/\/www.epilepsy.com\/advocacy\/priorities\/seizure-safe-schools; 2022 [accessed June 17, 2022]."},{"key":"10.1016\/j.ebr.2023.100612_b0180","doi-asserted-by":"crossref","first-page":"109002","DOI":"10.1016\/j.yebeh.2022.109002","article-title":"Written seizure action plans for adult patients with epilepsy: Distilling insights from emergency action plans for other chronic conditions","volume":"140","author":"Herman","year":"2023","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.ebr.2023.100612_b0185","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1186\/s12875-015-0352-4","article-title":"The 'vicious cycle' of personalised asthma action plan implementation in primary care: a qualitative study of patients and health professionals' views","volume":"16","author":"Ring","year":"2015","journal-title":"BMC Fam Pract"},{"key":"10.1016\/j.ebr.2023.100612_b0190","doi-asserted-by":"crossref","first-page":"108264","DOI":"10.1016\/j.yebeh.2021.108264","article-title":"Recommendations for development of acute seizure action plans (ASAPs) from an expert panel","volume":"123","author":"Penovich","year":"2021","journal-title":"Epilepsy Behav"},{"issue":"7","key":"10.1016\/j.ebr.2023.100612_b0195","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.2337\/dci20-0023","volume":"43","author":"Powers","year":"2020","journal-title":"Diabetes Care"},{"issue":"11","key":"10.1016\/j.ebr.2023.100612_b0200","first-page":"e6247","article-title":"The effectiveness of written asthma action plan at the National Guard Health Affairs' Asthma Clinic","volume":"11","author":"Goronfolah","year":"2019","journal-title":"Cureus"},{"issue":"12","key":"10.1016\/j.ebr.2023.100612_b0205","article-title":"Action plans with brief patient education for exacerbations in chronic obstructive pulmonary disease","volume":"12","author":"Howcroft","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.ebr.2023.100612_b0210","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.pediatrneurol.2020.04.005","article-title":"Implementation of a standardized seizure action plan to improve communication and parental education","volume":"112","author":"Neville","year":"2020","journal-title":"Pediatr Neurol"},{"key":"10.1016\/j.ebr.2023.100612_b0215","unstructured":"Massachusetts Department of Public Health. Adult Asthma Plan, https:\/\/massclearinghouse.ehs.state.ma.us\/PROG-ASTH\/AS911kit.html; 2023 [accessed January 13, 2023]."},{"issue":"2","key":"10.1016\/j.ebr.2023.100612_b0220","doi-asserted-by":"crossref","first-page":"144","DOI":"10.2174\/1567201819666220401091632","article-title":"Exploring nose to brain nano delivery for effective management of migraine","volume":"20","author":"Tanna","year":"2023","journal-title":"Curr Drug Deliv"},{"issue":"suppl 2","key":"10.1016\/j.ebr.2023.100612_b0225","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1111\/epi.14479","article-title":"Rescue therapies for seizure emergencies: new modes of administration","volume":"59","author":"Maglalang","year":"2018","journal-title":"Epilepsia"},{"issue":"1","key":"10.1016\/j.ebr.2023.100612_b0230","doi-asserted-by":"crossref","first-page":"13","DOI":"10.3109\/03602537808993775","article-title":"Dependence, tolerance, and addiction to benzodiazepines: clinical and pharmacokinetic considerations","volume":"8","author":"Greenblatt","year":"1978","journal-title":"Drug Metab Rev"},{"issue":"9481","key":"10.1016\/j.ebr.2023.100612_b0235","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/S0140-6736(05)66909-7","article-title":"Safety and efficacy of buccal midazolam versus rectal diazepam for emergency treatment of seizures in children: a randomised controlled trial","volume":"366","author":"McIntyre","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.ebr.2023.100612_b0240","doi-asserted-by":"crossref","first-page":"108013","DOI":"10.1016\/j.yebeh.2021.108013","article-title":"Examining the patient and caregiver experience with diazepam nasal spray for seizure clusters: results from an exit survey of a phase 3, open-label, repeat-dose safety study","volume":"121","author":"Penovich","year":"2021","journal-title":"Epilepsy Behav"},{"issue":"3","key":"10.1016\/j.ebr.2023.100612_b0245","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.eplepsyres.2013.02.018","article-title":"A pilot study assessing the bioavailability and pharmacokinetics of diazepam after intranasal and intravenous administration in healthy volunteers","volume":"105","author":"Agarwal","year":"2013","journal-title":"Epilepsy Res"},{"issue":"7","key":"10.1016\/j.ebr.2023.100612_b0250","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1056\/NEJMoa1107494","article-title":"Intramuscular versus intravenous therapy for prehospital status epilepticus","volume":"366","author":"Silbergleit","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ebr.2023.100612_b0255","doi-asserted-by":"crossref","first-page":"108989","DOI":"10.1016\/j.yebeh.2022.108989","article-title":"Psychosocial outcomes of repeated treatment of seizure clusters with midazolam nasal spray: results of a phase 3, open-label extension trial","volume":"138","author":"Meng","year":"2023","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.ebr.2023.100612_b0260","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.yebeh.2016.07.018","article-title":"Benzodiazepine use in seizure emergencies: a systematic review","volume":"63","author":"Haut","year":"2016","journal-title":"Epilepsy Behav"},{"issue":"2","key":"10.1016\/j.ebr.2023.100612_b0265","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1177\/1535759720987546","article-title":"Benzodiazepines for out-of-hospital status epilepticus: do or do not! there is no try!","volume":"21","author":"Gaspard","year":"2021","journal-title":"Epilepsy Curr"},{"key":"10.1016\/j.ebr.2023.100612_b0270","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.seizure.2018.05.021","article-title":"Timing in the treatment of status epilepticus: from basics to the clinic","volume":"68","author":"Gainza-Lein","year":"2019","journal-title":"Seizure"},{"issue":"7","key":"10.1016\/j.ebr.2023.100612_b0275","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1038\/s41582-022-00664-3","article-title":"Why won't it stop? The dynamics of benzodiazepine resistance in status epilepticus","volume":"18","author":"Burman","year":"2022","journal-title":"Nat Rev Neurol"},{"issue":"10","key":"10.1016\/j.ebr.2023.100612_b0280","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1111\/epi.13121","article-title":"A definition and classification of status epilepticus\u2013Report of the ILAE Task Force on Classification of Status Epilepticus","volume":"56","author":"Trinka","year":"2015","journal-title":"Epilepsia"},{"issue":"5","key":"10.1016\/j.ebr.2023.100612_b0285","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1212\/WNL.0000000000004176","article-title":"A meta-analysis on progressive atrophy in intractable temporal lobe epilepsy: Time is brain?","volume":"89","author":"Caciagli","year":"2017","journal-title":"Neurology"},{"issue":"11","key":"10.1016\/j.ebr.2023.100612_b0290","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.1111\/j.1528-1167.2005.00279.x","article-title":"Cognitive decline in severe intractable epilepsy","volume":"46","author":"Thompson","year":"2005","journal-title":"Epilepsia"},{"issue":"5 suppl","key":"10.1016\/j.ebr.2023.100612_b0295","doi-asserted-by":"crossref","first-page":"14S","DOI":"10.1177\/0883073807303065","article-title":"Who is at risk for prolonged seizures?","volume":"22","author":"Shinnar","year":"2007","journal-title":"J Child Neurol"},{"key":"10.1016\/j.ebr.2023.100612_b0300","doi-asserted-by":"crossref","first-page":"108550","DOI":"10.1016\/j.yebeh.2021.108550","article-title":"Comment on \u201cIntranasal midazolam versus intravenous\/rectal benzodiazepines for acute seizure control in children: a systematic review and meta-analysis\u201d","volume":"128","author":"Wheless","year":"2022","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.ebr.2023.100612_b0305","unstructured":"US Food and Drug Administration. Clinical Superiority Findings, https:\/\/www.fda.gov\/industry\/designating-orphan-product-drugs-and-biological-products\/clinical-superiority-findings; 2019 [accessed June 23, 2020]."},{"issue":"5","key":"10.1016\/j.ebr.2023.100612_b0310","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1111\/epi.14069","article-title":"Determination of minimal steady-state plasma level of diazepam causing seizure threshold elevation in rats","volume":"59","author":"Dhir","year":"2018","journal-title":"Epilepsia"},{"issue":"5","key":"10.1016\/j.ebr.2023.100612_b0315","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1111\/epi.16506","article-title":"Pharmacokinetics and safety of VALTOCO (NRL-1; diazepam nasal spray) in patients with epilepsy during seizure (ictal\/peri-ictal) and nonseizure (interictal) conditions: a phase 1, open-label study","volume":"61","author":"Hogan","year":"2020","journal-title":"Epilepsia"},{"issue":"3 Pt 1","key":"10.1016\/j.ebr.2023.100612_b0320","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1164\/ajrccm.156.3.9607013","article-title":"Reduced airway absorption in seasonal allergic rhinitis","volume":"156","author":"Greiff","year":"1997","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.ebr.2023.100612_b0325","doi-asserted-by":"crossref","DOI":"10.1016\/j.yebeh.2021.107898","volume":"118","author":"Vazquez","year":"2021","journal-title":"Epilepsy Behav"},{"issue":"8","key":"10.1016\/j.ebr.2023.100612_b0330","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1002\/j.1552-4604.1994.tb02051.x","article-title":"Nasal mucosal inflammation has no effect on the absorption of intranasal triamcinolone acetonide","volume":"34","author":"Argenti","year":"1994","journal-title":"J Clin Pharmacol"},{"issue":"1","key":"10.1016\/j.ebr.2023.100612_b0335","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1111\/j.1526-4610.2005.05005.x","article-title":"Zolmitriptan nasal spray exhibits good long-term safety and tolerability in migraine: results of the INDEX trial","volume":"45","author":"Dowson","year":"2005","journal-title":"Headache"}],"container-title":["Epilepsy & Behavior Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589986423000308?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589986423000308?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T00:08:10Z","timestamp":1762906090000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589986423000308"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023]]},"references-count":67,"alternative-id":["S2589986423000308"],"URL":"https:\/\/doi.org\/10.1016\/j.ebr.2023.100612","relation":{},"ISSN":["2589-9864"],"issn-type":[{"type":"print","value":"2589-9864"}],"subject":[],"published":{"date-parts":[[2023]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Acute seizure therapies in people with epilepsy: Fact or fiction? A U.S. Perspective","name":"articletitle","label":"Article Title"},{"value":"Epilepsy & Behavior Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ebr.2023.100612","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"100612"}}